BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37777425)

  • 1. Uncovering a dose-response relationship between positive fecal immunochemical test (FIT) and all-cause, cardiovascular and cancer-related mortality.
    Wen CP; Tsai MK; Lee JH; Chiou HY; Wen C; Chu TD; Chen CH
    Eur J Intern Med; 2024 Feb; 120():69-79. PubMed ID: 37777425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal haemoglobin concentrations are associated with all-cause mortality and cause of death in colorectal cancer screening.
    Kaalby L; Deding U; Al-Najami I; Berg-Beckhoff G; Bjørsum-Meyer T; Laurberg T; Shaukat A; Steele RJC; Koulaouzidis A; Rasmussen M; Kobaek-Larsen M; Baatrup G
    BMC Med; 2023 Jan; 21(1):29. PubMed ID: 36691009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive fecal immunochemical test results are associated with non-colorectal cancer mortality.
    Jung YS; Lee J; Moon CM
    Korean J Intern Med; 2022 Mar; 37(2):313-321. PubMed ID: 34579523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test.
    Pin-Vieito N; Iglesias MJ; Remedios D; Rodríguez-Alonso L; Rodriguez-Moranta F; Álvarez-Sánchez V; Fernández-Bañares F; Boadas J; Martínez-Bauer E; Campo R; Bujanda L; Ferrandez Á; Piñol V; Rodríguez-Alcalde D; Guardiola J; Cubiella J; On Behalf Of The Colonpredict Study Investigators
    World J Gastroenterol; 2020 Jan; 26(1):70-85. PubMed ID: 31933515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
    Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer.
    Zorzi M; Battagello J; Selby K; Capodaglio G; Baracco S; Rizzato S; Chinellato E; Guzzinati S; Rugge M
    Gut; 2022 Mar; 71(3):561-567. PubMed ID: 33789965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonoscopy decreases mortality in colorectal cancer patients compared with fecal immunochemical test.
    Sung SY; Choi HH; Kim S; Park BR; Kim YK; Kim HK; Cho YS; Kim SW; Kim SS; Chae HS
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1991-1997. PubMed ID: 35738218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.